It goes without saying that 2020 has been a strange year for us all. Whilst there have been many challenges to overcome, we are proud of the way we have adapted and turned 2020 into a successful year. In our annual year in review blog, we share our highlights and positive news from the past year.
Firstly, we would like to say a big thank you to all our clients and connections for the numerous recommendations and referrals we have received this year. We very much appreciate this support and we are delighted with our team of analysts for building such a strong reputation.
Demand for our Pathologist-led services continued to grow over the year, leading to our recruitment of an additional Senior Clinical Pathologist, read more on that here. We’ve also recently further expanded our team with Image Analysis Scientist Meredith and Project Manager Gabriel, with more new recruits planned for 2021.
Throughout 2020 we made significant improvements to our IT infrastructure so that we can deliver an even better service to our clients. We developed a proprietary image viewing portal, OBserver, that allows our clients to review images, annotations and overlays of studies performed on our Visiopharm software. More details on that to come in the new year.
To meet increasing demand from clients, we expanded our Visiopharm subscription model for unlimited processing capabilities on all software modules, including Visiopharm AI. We also incorporated the Indica Labs HALO AI module into our workflow to further strengthen our software capabilities.
We significantly increased our computing ‘firepower’ to speed up the delivery of data. We looked to AWS for a more flexible and scalable infrastructure with on demand access to GPUs and CPUs required for AI training and image processing – more on that here.
Earlier in the year, we were thrilled to be part of the INCISE project awarded an Innovate grant to develop a precision diagnostic tool to transform bowel cancer screening in the UK. We’re collaborating with the NHS, University of Glasgow, BioClavis and Canon Medical to utilise a combination of genomic and digital pathology data to predict patients likely to develop pre-cancerous polyps, enabling early detection of Colorectal Cancer (CRC). Read more on that here.
In July, we announced our partnership with Ultivue to provide pharmaceutical companies with an end-to-end workflow for gaining valuable insights from biomarkers in situ. If you’re interested in finding out more about our integrated offering, click here to watch our recent joint webinar in which we present an 8-plex staining protocol and detailed image analysis approach for the comprehensive assessment of the immune cell types and interactions within the TME.
Applying our Expertise
Despite the lockdown and restrictions, 2020 was our busiest year yet at OracleBio. The Image Analysis team have worked tirelessly on a variety of projects, the majority of which were Immuno-Oncology focused but there were also Fibrosis, Dermatology, Renal, Ophthalmology and Neurology studies.
We have seen a major upsurge in the requests for analysis of multiplex IF, with an ever increasing number of markers. Throughout the year we worked on a number of large clinical studies analysing 8-plex and more recently 12-plex IF staining. Check out the posters section of our website to see our multiplex posters from SITC and AACR this year.
And finally, what’s on the horizon for OracleBio?
We are excited about what lies in store for OracleBio in 2021. The company turns 10 in January and we have some exciting new services to launch so it’s already shaping up to be a big year. Our schedule for the first half of the year is already starting to fill up so if you are planning an image analysis study in 2021, we would encourage you to contact us now to start planning your study.
We’d like to take this opportunity to thank our clients, partners and suppliers for their continued support through a very unusual year. We look forward to working with you throughout 2021.
Reasons to work with OracleBio:
Data you can trust – We have thorough quality control procedures in place throughout our workflow to ensure the data we provide is of a high-quality standard
Latest technologies – We continually invest time and money into the latest software and techniques so you don’t need to
Find out more about our Software Capabilities
OracleBio's Quantitative Digital Pathology Services
Stay up to date with OracleBio
Sign up to our mailing list to stay informed about news, webinars, events and more